OTC Markets Group Welcomes Safeguard Scientifics, Inc. to OTCQX
Frontline Workers Have Greater Mental Health Needs, Yet Are Less Likely to Seek Help, Study Finds
Sector Update: Financial Stocks Mixed Friday Afternoon
Safeguard Scientifics Prepares for Stock Delisting
Safeguard Scientifics Filed Form 25 to Voluntarily Delist Its Common Stock From The Nasdaq Stock Market LLC
MeQuilibrium Selected by Point32Health to Support Emotional Health and Well-being of Their Colleagues
Safeguard Scientifics Plans Delisting and OTC Market Move
Safeguard Scientifics Filed to Effectuate Reverse Stk Split at Ratio of 1-For-100, Followed Immediately by Forward Stk Split at Ratio of 100-For-1
Safeguard Scientifics Intends to File Form 25 to Voluntarily Delist Its Common Stock From The Nasdaq Stock Market LLC
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Safeguard Scientifics Announces Effective Date Of 1-For-100 Reverse Stock Split Followed By A 100-For-1 Forward Stock Split; Appoints Mark Dow As CEO, CFO And Secretary
Safeguard Scientifics Names Mark Dow as CEO >SFE
Safeguard Scientifics Announces Effective Date of Stock Splits to Effectuate the Going Dark Transaction and New Chief Executive Officer and Chief Financial Officer
Safeguard Scientifics To Go Ex-Dividend On December 29th, 2023 With 0.35 USD Special Dividend Per Share
December 22nd - $Safeguard Scientifics(SFE.US)$ is trading ex-dividend on December 29th, 2023. Shareholders of record on December 19th, 2023 will receive 0.35 USD special dividend per share on Dec
Safeguard Scientifics Announced Company's Board Of Directors Determined The Reverse Stock Split Ratio To Be 1-For-100 And The Forward Stock Split Ratio To Be 100-For-1
Safeguard Scientifics Announces Stock Split Ratios to Effectuate the Going Dark Transaction
Safeguard Scientifics Declares $0.35 Special Dividend
Safeguard Scientifics' Board of Directors Declares Contingent Cash Dividend of $0.35 Per Share
Syapse and FDA Extend Collaboration to Advance the Use of Real-World Data (RWD) and Inform Regulatory Science in Oncology